Viral Clearance Market Size, Share, Growth Analysis, By Type(Viral Removal Method, Viral Inactivation Method, Viral Detection Method), By Application(Recombinant Proteins, Blood, Blood Products, Vaccines), By End User(Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Others), By Method(Viral Removal Method, Viral Inactivation Method, Viral Detection Method), By Region - Industry Forecast 2024-2031

The key players in the viral clearance market are working on continuous innovation in the field of research and development and product portfolio enhancement for better therapeutic outcomes for consumers. For example, In November 2021, Wuxi biologics announced the official opening of its advanced therapies testing facility, including 140,000 sq. ft laboratories to enhance the company’s Contract Testing, Developing, and manufacturing Organization businesses to meet the increasing needs of customers in cell and gene therapy industry. Companies are also focusing on mergers and acquisitions to expand their businesses.

Viral Clearance Market Top Players Company Profiles

• Charles River Laboratories 
• Merck KGaA 
• Texcell 
• WuXi AppTec 
• Sartorius AG 
• Eurofins Scientific 
• Vironova 
• Syngene International 
• Microbac Laboratories 
• Creative Biolabs 
• Nelson Labs 
• SGS AG 
• Lonza Group 
• Bioscience Laboratories 
• Labor Dr. Merk & Kollegen 
• Gilead Sciences 
• Poolbeg Pharma 
• Incyte 
• Genmab 
• Biogen 

Viral Clearance Market Recent Development

• In June 2022, Asahi Kasei Medical is expanding into the CDMO business with the acquisition of Bay Area biologics maker Bionova Scientific for an undisclosed price. Like many in the industry, Japan-based Asahi Kasei has been on an expansion tear during the past few years. It purchased Austrian viral safety testing services provider Virusure Forschung und Entwicklung in 2019 and last year snapped up U.S-based mycoplasma testing services company Bionique Testing Labs.
• In August 2021, WuXi Biologics announced that just 13 months after receiving its first GMP certificate, it has also received European Medicines Agency (EMA) GMP certificate for Biosafety testing center in Suzhou. This certificate demonstrates WuXi Biologics’ compliance with international cGMP safety assessment standards and regulatory guidelines.